Back to top
more

UnitedHealth Group (UNH)

(Real Time Quote from BATS)

$569.97 USD

569.97
2,044,992

+3.94 (0.70%)

Updated Oct 18, 2024 02:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 7% (233 out of 250)

Industry: Medical - HMOs

Better trading starts here.

Zacks News

Charles River (CRL) Q1 Earnings Top, Gross Margin Falls

Charles River (CRL) Q1 results highlight 9.8% organic revenue growth, driven by strength across all three segments.

CVS Health (CVS) Q1 Earnings Top Estimates, '22 EPS View Up

CVS Health (CVS) reports better-than-expected results for Q1, with robust segmental performance driving the top line.

Masimo's (MASI) Q1 Earnings Surpass Estimates, FY22 View Up

Masimo's (MASI) robust product shipments drive its Q1 sales.

Cerner (CERN) Q1 Earnings in Line, Revenues Lag Estimates

Cerner's (CERN) first-quarter results benefit from gains across four of its business units.

PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates

PerkinElmer's (PKI) first-quarter results benefit from a solid performance at Discover & Analytics Solutions business.

IDEXX (IDXX) Q1 Earnings Surpass Estimates, Margins Down

Strong sales at the CAG and Water businesses drove IDEXX's (IDXX) first-quarter 2022 revenues.

AmerisourceBergen (ABC) Q2 Earnings & Revenues Top Estimates

AmerisourceBergen's (ABC) fiscal second-quarter results benefit from segmental growth.

Should Vanguard Mega Cap Value ETF (MGV) Be on Your Investing Radar?

Style Box ETF report for MGV

Zimmer Biomet (ZBH) Q1 Earnings Top Estimates, FY22 View Up

Each of Zimmer Biomet's (ZBH) geographic segments and product divisions recorded year-over-year sales growth at CER.

Catalent (CTLT) Q3 Earnings Beat Estimates, FY22 View Up

Catalent's (CTLT) robust performance across most of its segments drives its third-quarter fiscal 2022 top line.

Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now

Investors are optimistic about Quest Diagnostics (DGX) owing to a strong recovery in base business and raised 2022 outlook.

Integer Holdings (ITGR) Q1 Earnings, Revenues Lag Estimates

Integer Holdings' (ITGR) first-quarter results reflect robust segmental performances besides strength in the majority of the product lines.

Integra (IART) Q1 Earnings Top Estimates, Margins Expand

Integra's (IART) updated 2022 financial guidance calls for strong year-over-year organic growth.

Syneos Health (SYNH) Q1 Earnings Top Estimates, Margins Up

Syneos Health's (SYNH) revenues increased year over year in the first quarter, led by strong performances by the Clinical Solutions and Commercial Solutions arms.

Surmodics (SRDX) Beats on Q2 Earnings, Revises FY22 View

Despite solid IVD revenues, Surmodics (SRDX) reports a soft Q2 overall top line.

Teleflex's (TFX) Q1 Earnings Top Estimates, Margins Down

Teleflex (TFX) exhibits year-over-year growth across the Americas, EMEA and Asia regions at CER in the first quarter.

Accuray (ARAY) Q3 Earnings Beat Estimates, Revenues Lag

Despite strong product demand, Accuray (ARAY) reports an overall soft Q3 performance.

Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Up

Bio-Rad's (BIO) first-quarter 2022 revenues decline year over year due to lower COVID-related demand.

QIAGEN (QGEN) Q1 Earnings Surpass Estimates, 2022 View Up

QIAGEN (QGEN) exited first-quarter 2022 with better-than-expected results on strength in the non-COVID product portfolio driving the top line.

Stryker (SYK) Q1 Earnings and Revenues Surpass Estimates

Stryker's (SYK) first-quarter earnings reflect strong performance across its segments.

DexCom (DXCM) Q1 Earnings Miss, Revenues Beat Estimates

Despite a decline in bottom line, DexCom's (DXCM) first-quarter results benefit from domestic and international revenue growth and solid new customer additions.

Merit Medical (MMSI) Q1 Earnings Beat, FY22 View Unchanged

Merit Medical (MMSI), in the first quarter, benefits from revenue growth in both its segments and from all of the product categories within its Cardiovascular unit.